Hodgkin lymphoma: postrelapse survival poorer in nonwhite children, adolescents

  • Kahn JM & al.
  • J Clin Oncol
  • 20 sept. 2019

  • de David Reilly
  • Univadis Clinical Summaries
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Takeaway

  • Nonwhite pediatric and adolescent patients with de novo Hodgkin lymphoma (HL) treated in Children’s Oncology Group (COG) studies experienced significantly worse OS, which was driven by postrelapse mortality.

Why this matters

  • Annual incidence of HL in the United States among children and adolescents is approximately 1200.

Study design

  • COG pooled analysis of 3 phase 3 trials in years 2002-2012 (n=1605) to investigate the effect of race/ethnicity on survival in non-Hispanic white (NHW; n=1083), non-Hispanic black (NHB; n=210), and Hispanic (n=312) patients aged 
  • Funding: Children’s Oncology Group; National Clinical Trials Network; St Baldrick’s Foundation; Lymphoma Research Foundation; Irving Institute for Clinical and Translational Research at Columbia University Irving Medical Center.

Key results

  • No significant difference between NHW and nonwhite patients in:
    • 5-year event-free survival: adjusted analysis, P=.62; unadjusted analysis, P=.60.  
    • 5-year OS: unadjusted analysis, P=.06.  
  • In multivariable analysis vs NHW children:
    • Significantly increased risk of all-cause mortality in nonwhite children: HR, 1.88; 95% CI, 1.06-3.33; P=.031.
    • Significantly increased risk of postrelapse mortality: HR for NHB, 3.45 (95% CI, 1.46-8.16; P=.005); HR for Hispanic, 2.72 (95% CI, 1.19-6.23; P=.018).

Limitations

  • Data incomplete for select variables.